Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Clinical trial NCT02356458 · TERMINATED

Trial details

NCT number: NCT02356458
Sponsor: Swiss Cancer Institute
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma

Start date: 2015-08-31
Primary completion: 2021-03-30
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.